Metabolic tumor volume assessed by18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1829-1835

  Fonti, Rosa ^a   Larobina, Michele ^a   Del Vecchio, Silvana ^a   De Luca, Serena ^a   Fabbricini, Rossella ^a   Catalano, Lucio ^a   Pane, Fabrizio ^a   Salvatore, Marco ^a   Pace, Leonardo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

18F FDG PET CT; Metabolic tumor volume; Multiple myeloma; Prognosis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; LENALIDOMIDE; M PROTEIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG TUMOR LEVEL; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; METABOLIC TUMOR VOLUME; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84870369288     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.106500     Document Type: Article

References (35)

1. Malpas JS, Caroll JJ. Myeloma: clinical presentation and diagnosis. In: Malpas JS, Bergsagel DE, Kyle RA, eds. Myeloma: Biology and Management. New York, NY: Oxford University Press; 1995:169.
2. Drach J, Sagaster V, Ackermann J, Kaufmann H. Prognostic factors for multiple myeloma. Hematology. 2006;2:196-200.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3-9.
4. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cells mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842-854.
5. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379-398. (Pubitemid 38088783)
6. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539-1543. (Pubitemid 44137426)
7. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335-1341.
8. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med. 2008;38:141-148. (Pubitemid 351163195)
9. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007; 69:328-333. (Pubitemid 47380105)
10. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80: 2505-2509. (Pubitemid 28009506)
11. Basu S, Saboury B, Torigian DA, Alavi A. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801-811.
12. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861-5868.
13. 18F-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
14. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008;29:521-526. (Pubitemid 351643419)
15. 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:494-504.
16. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340-347.
17. 18F-FDG PET and MRI. J Nucl Med. 2009;50:1435-1440.
18. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-1584.
19. Smith A, Wisloff F, Samson D. UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410-451.
20. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011;29:1907-1915.
21. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989-5995.
22. 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195-200.
23. Bird JM, Owen RG, D'Sa S, et al. Haemato-oncology Task Force of the British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines on the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154:32-75.
24. Dimopoulos M, Terpos E, Comenzo RL, et al. IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23:1545-1556.
25. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-2076.
26. Lütje S, de Rooy JW, Croockewit S, Koedam E, Oyen WJ, Raymakers RA. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol. 2009;88:1161-1168.
27. 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525-531.
28. 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-55.
29. Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33:819-823.
30. Berghmans T, Dusart M, Paesmans M, et al European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6-12.
31. 18F- fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging. 2010;37:1087-1094.
32. Chatterton BE, Ho Shon I, Baldey A, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:354-361.
33. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:1085-1093.
34. 18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010;10:667-674.
35. 18F- fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046-1053.